Share
1,247 Posts.
lightbulb Created with Sketch. 277
clock Created with Sketch. 05/03/25
18:32
Share
Originally posted by AlCp:
↑
I've provided you facts about those 3 IP being more advanced than just Ph1/b clinical trial to near development stages which will attract T/O from BP, if you are clueless about what I said and their market potential then that's your problem. HER-Vaxx's market was limited to just advanced gastric cancer to be used with chemotherapy, I still think there's value as there a potential the IP can be advanced to use as a combination with chemotherapy for other cancer treatment and not all alternate treatment will work on patient so chemotherapy will be their last option but BP seem to want to invest in alternate treatment and not chemotherapy????
Expand
I must have missed these facts. Can you please reply here with the facts and your sources for not only my benefit, but the benefit of all reading?
(20min delay)